435 assets in Melanoma

Therapeutic assets addressing Melanoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cediranib Melanoma	M.D. Anderson Cancer Center	P3	BBB (72)
Sargramostim Melanoma	Mayo Clinic	P3	BBB (72)
Cyclophosphamide Melanoma	Primmune Therapeutics, Inc.	P4	BB (70)
Dacarbazine Melanoma	Suzhou BlueHorse Therapeutics Co., Ltd.	P3	BB (70)
Tebentafusp Melanoma	Immunocore Ltd	P3	BB (70)
Ipilimumab Melanoma	M.D. Anderson Cancer Center	P4	BB (69)
Nivolumab Melanoma	Bristol-Myers Squibb	P4	BB (69)
Pembrolizumab Melanoma	Biocon Biologics UK PLC	P4	BB (69)
Trametinib Melanoma	Xynomic Pharmaceuticals, Inc.	P4	BB (69)
Tunlametinib Melanoma	Fudan University	P4	BB (67)
Dabrafenib Melanoma	Intergruppo Melanoma Italiano	P4	BB (66)
Vemurafenib Melanoma	Cancer Research UK	P3	BB (66)
Ziv-Aflibercept Melanoma	National Cancer Institute (NCI)	P2	BB (66)
Carboplatin Melanoma	Rapa Therapeutics LLC	P3	BB (64)
Fluorouracilum Melanoma	Neonc Technologies, Inc.	P2	BB (64)
Interferon Alfa-2B Melanoma	Roswell Park Cancer Institute	P3	BB (64)
Toripalimab Melanoma	West China Hospital	P3	BB (64)
Irinotecan Melanoma	Pfizer	P2	B (63)
Poly-Iclc Melanoma	Washington University School of Medicine	P2	B (63)
Relatlimab Melanoma	Bristol-Myers Squibb	P4	B (63)
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- Melanoma	National Cancer Institute (NCI)	P2	B (62)
Apsolol Melanoma	Sarah Weiss	P2/3	B (62)
Cis-Diamminedichloroplatinum Ii Melanoma	Suzhou BlueHorse Therapeutics Co., Ltd.	P3	B (62)
Cobimetinib Melanoma	ImmVira Pharma Co. Ltd	P3	B (62)
Fibromun Melanoma	Philogen S.p.A.	P3	B (62)
Fludarabine Melanoma	Beijing Biotech	P2	B (62)
ICP34.5-, ICP47-DELETED HERPES SIMPLEX VIRUS 1 (HSV-1) INCORPORATING THE HUMAN GM-CSF GENE Melanoma	Amgen	P3	B (62)
Imiquimod Melanoma	Toray Industries, Inc	P2	B (62)
Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer Melanoma	Fujian Cancer Hospital	P3	B (62)
Lenvatinib Melanoma	Diwakar Davar	P3	B (62)
Pegyinterferon-Alfa-2A Melanoma	Diakonos Oncology Corporation	P2/3	B (62)
Resiquimod Melanoma	Institut Bergonié	P2	B (62)
TIL Melanoma	City of Hope Medical Center	P3	B (62)
Atezolizumab Melanoma	National Cancer Institute (NCI)	P3	B (61)
Docetaxel Melanoma	NuCana plc	P2	B (61)
Durvalumab Melanoma	AstraZeneca	P2	B (61)
Prednisone Melanoma	National Cancer Institute (NCI)	P2	B (61)
Ribociclib Melanoma	Melanoma Institute Australia	P2	B (61)
Binimetinib Melanoma	The Christie NHS Foundation Trust	P3	B (60)
Cabozantinib Melanoma	National Cancer Institute (NCI)	P2	B (60)
Dinaciclib Melanoma	National Cancer Institute (NCI)	P2	B (60)
Encorafenib Melanoma	The Christie NHS Foundation Trust	P3	B (60)
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer Melanoma	M.D. Anderson Cancer Center	P3	B (60)
Oncos-102 Melanoma	Targovax Oy	P2	B (60)
Oxaliplatin Melanoma	Pfizer	P2	B (60)
Prolgolimab Melanoma	Biocad	P3	B (60)
Sorafenib Melanoma	Charite University, Berlin, Germany	P3	B (60)
Tocilizumab Melanoma	University of Southern California	P2	B (60)
Bcd-263 Melanoma	Biocad	P3	B (59)
Imatinib Melanoma	University of California, San Francisco	P2	B (59)

Showing 1 to 50 of 435 assets

PreviousPage 1 of 9Next